IBM Watson and Pfizer reached a new agreement, the former will be the supercomputing capacity for cancer drug development.

Pfizer will use Watson for Drug Discovery’s machine learning, natural language processing and other cognitive reasoning capabilities for new drug identification, combination therapy and patient selection strategies in immuno-oncology.

Watson for Drug Discovery is a new cloud platform designed to help life sciences discover new drug targets and indications for alternative drugs. Watson’s main attraction is its ability to handle massive amounts of information, which can help researchers view different datasets, discover new associations through dynamic visualization, and suggest hidden patterns. nud4700snt1g

Researchers read 200-300 papers a year on average, while Watson has read 25 million abstracts on Medline, more than 1 million full-text medical articles, and 4 million patent documents, all of which are regularly updated. According to Pfizer, many researchers believe that the future of immuno-oncology is a combination of unique tumor characteristics that will change the paradigm of cancer treatment, so that more cancer patients get treatment. The use of Watson’s cognitive ability in drug development may lead to a new, potentially new, immunotherapy of cancer in patients. tps54620rgyt

Immuno-oncology is a cancer treatment that uses the body’s immune system to help combat cancer. Pfizer will use Watson to analyze a large number of heterogeneous data, including authorized and public data, as well as Pfizer private data to analyze and test theoretical assumptions, gain new insights.